
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical Ltd has recently achieved a significant operational milestone by securing a radioactive material license in New Hampshire and completing the first phase of its commercial-scale manufacturing facility, positioning the company to begin U.S. manufacturing of its Alpha DaRT technology in 2026. The company's strong cash position indicates financial stability and potential for future growth as it seeks to address unmet needs in oncology with its innovative treatment approach. Although the reported net loss was slightly higher than anticipated, the strategic advancements in manufacturing and regulatory approvals suggest a positive trajectory for the company as it prepares to expand its market presence.
Bears say
Alpha Tau Medical reported a net loss of $11.7 million for the third quarter of 2025, highlighting significant financial challenges. The company faces considerable risks including the potential failure of its Alpha DaRT technology in clinical trials and the ongoing uncertainty surrounding its ability to secure U.S. regulatory approval. Additionally, there are concerns regarding the commercial viability of Alpha DaRT due to market size, competitive pressures, and the risk of shareholder dilution, which contribute to a negative outlook on the stock's performance.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares